GB202101299D0 - Diagnostic polypetides and methods - Google Patents

Diagnostic polypetides and methods

Info

Publication number
GB202101299D0
GB202101299D0 GBGB2101299.2A GB202101299A GB202101299D0 GB 202101299 D0 GB202101299 D0 GB 202101299D0 GB 202101299 A GB202101299 A GB 202101299A GB 202101299 D0 GB202101299 D0 GB 202101299D0
Authority
GB
United Kingdom
Prior art keywords
polypetides
diagnostic
methods
diagnostic polypetides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2101299.2A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avacta Life Sciences Ltd
Original Assignee
Avacta Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2008694.8A external-priority patent/GB202008694D0/en
Priority claimed from GBGB2014725.2A external-priority patent/GB202014725D0/en
Application filed by Avacta Life Sciences Ltd filed Critical Avacta Life Sciences Ltd
Priority to GBGB2103142.2A priority Critical patent/GB202103142D0/en
Publication of GB202101299D0 publication Critical patent/GB202101299D0/en
Priority to PCT/EP2021/064289 priority patent/WO2021249786A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host
GBGB2101299.2A 2020-06-09 2021-01-29 Diagnostic polypetides and methods Ceased GB202101299D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2103142.2A GB202103142D0 (en) 2020-06-09 2021-03-05 Diagnostic polypeptides and methods
PCT/EP2021/064289 WO2021249786A1 (en) 2020-06-09 2021-05-27 Sars-cov2 diagnostic polypeptides and methods

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2008694.8A GB202008694D0 (en) 2020-06-09 2020-06-09 Pathogen binding polypeptides, and uses related thereto
GBGB2014725.2A GB202014725D0 (en) 2020-09-18 2020-09-18 Diagnostic polypeptides and methods

Publications (1)

Publication Number Publication Date
GB202101299D0 true GB202101299D0 (en) 2021-03-17

Family

ID=74865382

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB2101299.2A Ceased GB202101299D0 (en) 2020-06-09 2021-01-29 Diagnostic polypetides and methods
GBGB2103142.2A Ceased GB202103142D0 (en) 2020-06-09 2021-03-05 Diagnostic polypeptides and methods

Family Applications After (1)

Application Number Title Priority Date Filing Date
GBGB2103142.2A Ceased GB202103142D0 (en) 2020-06-09 2021-03-05 Diagnostic polypeptides and methods

Country Status (2)

Country Link
GB (2) GB202101299D0 (en)
WO (1) WO2021249786A1 (en)

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US216034A (en) 1879-06-03 Improvement in weather-strips for doors
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
DE2201111A1 (en) 1971-01-19 1972-07-27 Niro Atomizer As Atomization drying device for the production of powder, e.g. Milk powder
US3805783A (en) 1971-02-12 1974-04-23 A Ismach Hand powered hypodermic jet injector gun
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4342310A (en) 1980-07-08 1982-08-03 Istvan Lindmayer Hydro-pneumatic jet injector
ATE12348T1 (en) 1980-11-10 1985-04-15 Gersonde Klaus Prof Dr PROCESS FOR THE PRODUCTION OF LIPID VESICLES BY ULTRASONIC TREATMENT, APPLICATION OF THE PROCESS AND DEVICE FOR CARRYING OUT THE PROCESS.
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
EP0088046B1 (en) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipids in the aqueous phase
US4447223A (en) 1982-04-16 1984-05-08 Cct Associates Medicament implant applicator
DE3218121A1 (en) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Pharmaceutical compositions for tumour treatment
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4454106A (en) 1982-06-07 1984-06-12 Gansow Otto A Use of metal chelate conjugated monoclonal antibodies
EP0102324A3 (en) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipids and surfactants in an aqueous medium
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3483949D1 (en) 1983-09-26 1991-02-21 Udo Dr Med Ehrenfeld AGENT AND PRODUCT FOR THE DIAGNOSIS AND THERAPY OF TUMORS AND FOR THE TREATMENT OF WEAKNESSES OF THE CELLED AND HUMORAL IMMUNE DEFENSE.
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
JP2532858B2 (en) 1985-04-01 1996-09-11 セルテツク リミテツド Transformed myeloma cell line
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US6024983A (en) 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5175154A (en) 1987-11-25 1992-12-29 Research Corporation Technologies, Inc. 5 α-pregnan-20-ones and 5-pregnen-20-ones and related compounds
EP0391960B1 (en) 1987-12-11 1994-08-17 Whitehead Institute For Biomedical Research Genetic modification of endothelial cells
WO1990006997A1 (en) 1988-12-13 1990-06-28 United States Government As Represented By The Secretary Of The Department Of Health And Human Services Genetically engineered endothelial cells and use thereof
WO1990014363A1 (en) 1989-05-19 1990-11-29 Amgen Inc. Metalloproteinase inhibitor
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
KR920007887B1 (en) 1989-08-29 1992-09-18 스즈키 지도오샤 고오교오 가부시키가이샤 Exhaust gas cleaning device for internal combustion engine
US5360478A (en) 1989-10-16 1994-11-01 Phasex Corporation Gas anti-solvent recrystallization process
EP1285967A3 (en) 1990-09-21 2005-03-02 Chiron Corporation Human retroviral packaging cell line
EP0572401B2 (en) 1991-02-19 2007-11-07 The Regents of the University of California Viral particles having altered host range
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US5545130A (en) 1992-04-08 1996-08-13 Genetronics, Inc. Flow through electroporation method
US5389263A (en) 1992-05-20 1995-02-14 Phasex Corporation Gas anti-solvent recrystallization and application for the separation and subsequent processing of RDX and HMX
US5674703A (en) 1992-12-02 1997-10-07 Woo; Savio L. C. Episomal vector systems and related methods
WO1994015635A1 (en) 1993-01-11 1994-07-21 Dana-Farber Cancer Institute Inducing cytotoxic t lymphocyte responses
FR2702160B1 (en) 1993-03-02 1995-06-02 Biovecteurs As Synthetic particulate vectors and method of preparation.
US5993434A (en) 1993-04-01 1999-11-30 Genetronics, Inc. Method of treatment using electroporation mediated delivery of drugs and genes
US5702359A (en) 1995-06-06 1997-12-30 Genetronics, Inc. Needle electrodes for mediated delivery of drugs and genes
FR2704145B1 (en) 1993-04-21 1995-07-21 Pasteur Institut Particulate vector and pharmaceutical composition containing it.
US5407606A (en) 1994-01-10 1995-04-18 Tennessee Valley Authority Oriented spray-assisted cooling tower
US5505697A (en) 1994-01-14 1996-04-09 Mckinnon, Jr.; Charles N. Electrically powered jet injector
FR2723849B1 (en) 1994-08-31 1997-04-11 Biovector Therapeutics Sa PROCESS FOR INCREASING IMMUNOGENICITY, PRODUCT OBTAINED AND PHARMACEUTICAL COMPOSITION
US5660835A (en) 1995-02-24 1997-08-26 East Carolina University Method of treating adenosine depletion
US5736537A (en) 1995-09-12 1998-04-07 Estee Lauder, Inc. Dehydroep:androsterone sailcylate useful against skin atrophy
US6080728A (en) 1996-07-16 2000-06-27 Mixson; A. James Carrier: DNA complexes containing DNA encoding anti-angiogenic peptides and their use in gene therapy
DE69704206T2 (en) 1996-08-16 2001-08-30 Medical Res Council London SELF-REPLICATING EPISOMAL EXPRESSION VECTORS, WHICH CONVEY TISSUE-SPECIFIC EXPRESSION
JP4203835B2 (en) 1996-08-19 2009-01-07 アメリカ合衆国 Novel liposomal complexes that increase systemic delivery
US5869326A (en) 1996-09-09 1999-02-09 Genetronics, Inc. Electroporation employing user-configured pulsing scheme
US6055453A (en) 1997-08-01 2000-04-25 Genetronics, Inc. Apparatus for addressing needle array electrodes for electroporation therapy
US6241701B1 (en) 1997-08-01 2001-06-05 Genetronics, Inc. Apparatus for electroporation mediated delivery of drugs and genes
GB2330907A (en) 1997-10-28 1999-05-05 Applied Imaging Int Ltd A karyotyper and methods for producing karyotypes
US6208893B1 (en) 1998-01-27 2001-03-27 Genetronics, Inc. Electroporation apparatus with connective electrode template
US6009347A (en) 1998-01-27 1999-12-28 Genetronics, Inc. Electroporation apparatus with connective electrode template
US6120493A (en) 1998-01-27 2000-09-19 Genetronics, Inc. Method for the introduction of therapeutic agents utilizing an electroporation apparatus
US6451349B1 (en) 1998-08-19 2002-09-17 Quadrant Healthcare (Uk) Limited Spray-drying process for the preparation of microparticles
AU761522B2 (en) 1998-07-13 2003-06-05 Genetronics, Inc. Method and apparatus for electrically assisted topical delivery of agents for cosmetic applications
US6192270B1 (en) 1998-08-14 2001-02-20 Genetronics, Inc. Apparatus and method for the delivery of drugs and genes into tissue
US6150148A (en) 1998-10-21 2000-11-21 Genetronics, Inc. Electroporation apparatus for control of temperature during the process
EP2264166B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
WO2000067837A1 (en) 1999-05-10 2000-11-16 Gentronics, Inc. Method of electroporation-enhanced delivery of active agents
US7171264B1 (en) 1999-05-10 2007-01-30 Genetronics, Inc. Intradermal delivery of active agents by needle-free injection and electroporation
SE516924C2 (en) 2000-07-20 2002-03-26 Mattias Lundin Holding device for tacos
US6458738B1 (en) 2000-09-22 2002-10-01 Union Carbide Chemicals & Plastics Technology Corporation Spray-drying compositions and methods of spray-drying
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
GB0108968D0 (en) 2001-04-10 2001-05-30 Imp College Innovations Ltd Methods
JP3543326B2 (en) 2001-08-30 2004-07-14 ソニー株式会社 Information processing apparatus and method, information processing system, information distribution apparatus, recording medium, and program
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
EP3299393A1 (en) 2002-11-08 2018-03-28 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
US7790446B2 (en) 2005-02-11 2010-09-07 Kosagen Cell Factory Oü Vectors, cell lines and their use in obtaining extended episomal maintenance replication of hybrid plasmids and expression of gene products
US8101169B2 (en) 2005-02-23 2012-01-24 The Board Of Trustees Of The Leland Stanford Junior University Ocular gene therapy using avalanche-mediated transfection
US7923251B2 (en) 2005-02-23 2011-04-12 The Board Of Trustees Of The Leland Stanford Junior University Method and apparatus for avalanche-mediated transfer of agents into cells
PL1888640T3 (en) 2005-05-18 2012-08-31 Ablynx Nv Improved nanobodies against tumor necrosis factor-alpha
AU2006256530B2 (en) 2005-06-10 2012-12-20 United Kingdom Research And Innovation Scaffold
US8399201B2 (en) 2005-10-31 2013-03-19 Janssen Pharmaceutica N.V. Polypeptide complex of TRPM8 and calmodulin and its uses thereof
US8629244B2 (en) 2006-08-18 2014-01-14 Ablynx N.V. Interleukin-6 receptor binding polypeptides
JP4616237B2 (en) 2006-11-07 2011-01-19 日本電信電話株式会社 Method for forming silicon compound thin film
EP1995327A1 (en) 2007-05-21 2008-11-26 Humboldt Universität zu Berlin Probe for detecting a particular nucleic acid sequence
MX2009012650A (en) 2007-05-24 2010-02-18 Ablynx Nv Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders.
WO2009003177A1 (en) 2007-06-27 2008-12-31 Inbios International, Inc. Lateral flow assay system and methods for its use
DE102007052517A1 (en) 2007-10-29 2009-04-30 Autoimmun Diagnostika Gmbh ELISPOT process with two filter systems
MX2010005783A (en) 2007-11-27 2010-08-10 Ablynx Nv Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same.
GB0807065D0 (en) 2008-04-18 2008-05-21 Univ Leeds Novel scaffolds
BRPI0919113A2 (en) 2008-09-26 2016-08-09 Tocagen Inc isolated polynucleotide, substantially purified polypeptide, vector, host cell, recombinant reapply competent retrovirus, and methods for treating an individual with a proliferative cell disorder, and for treating a proliferative cell disorder in an individual
US8829173B2 (en) 2008-09-26 2014-09-09 Tocagen Inc. Recombinant vectors
US10316333B2 (en) 2009-06-17 2019-06-11 Tocagen Inc. Producer cells for replication competent retroviral vectors
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
US9669049B2 (en) 2010-10-31 2017-06-06 Tocagen Inc. Compositions comprising gamma retrovirus vectors and methods of treating proliferative disorders
US9405700B2 (en) 2010-11-04 2016-08-02 Sonics, Inc. Methods and apparatus for virtualization in an integrated circuit
AU2013243949A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
ES2786051T3 (en) 2012-10-25 2020-10-08 Tocagen Inc Retroviral vector with mini-promoter cassette
US9020605B2 (en) 2012-10-25 2015-04-28 Oncosec Medical Incorporated Electroporation device
GB201302597D0 (en) 2013-02-14 2013-04-03 Univ Leeds Novel Synthetic Proteins
CA2920049A1 (en) 2013-08-05 2015-02-12 Tocagen Inc. Recombinant vector with optimized a-bulge
AU2014315287A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
EP2918275B1 (en) 2013-12-13 2016-05-18 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
EP3092250A4 (en) 2014-01-08 2017-05-24 Moderna Therapeutics, Inc. Polynucleotides for the in vivo production of antibodies
ES2736127T3 (en) 2014-03-20 2019-12-26 Bristol Myers Squibb Co Type III domains of seroalbumin binding fibronectin
CA2943640A1 (en) 2014-03-26 2015-10-01 Tocagen Inc. A retroviral vector having immune-stimulating activity
WO2015196118A1 (en) 2014-06-19 2015-12-23 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
US20170175129A1 (en) 2014-06-19 2017-06-22 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
US10286086B2 (en) 2014-06-19 2019-05-14 Modernatx, Inc. Alternative nucleic acid molecules and uses thereof
US20170204152A1 (en) 2014-07-16 2017-07-20 Moderna Therapeutics, Inc. Chimeric polynucleotides
ES2809734T3 (en) 2015-01-09 2021-03-05 Oncosec Medical Inc Gene therapy and electroporation for the treatment of malignant neoplasms
US20180000953A1 (en) 2015-01-21 2018-01-04 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
EP3247398A4 (en) 2015-01-23 2018-09-26 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
JP6879996B2 (en) 2015-03-26 2021-06-02 オンコセック メディカル インコーポレイテッド How to treat malignant tumors
US11318305B2 (en) 2015-03-31 2022-05-03 Oncosec Medical Incorporated Systems and methods for improved tissue-sensing based electroporation
AU2016315444B2 (en) 2015-08-28 2023-02-23 BioNTech SE Method for reducing immunogenicity of RNA
AU2016317936A1 (en) 2015-09-04 2018-03-08 Tocagen Inc. Recombinant vectors comprising 2A peptide
DK3350333T3 (en) 2015-09-17 2022-01-31 Modernatx Inc POLYNUCLEOTIDES CONTAINING A STABILIZING TAIL REGION
US10766946B2 (en) 2015-09-23 2020-09-08 Bristol-Myers Squibb Company Fast-off rate serum albumin binding fibronectin type III domains
JP7079729B2 (en) 2015-12-18 2022-06-02 オンコセック メディカル インコーポレイテッド Plasmid constructs for heterologous protein expression and how to use them
WO2017162266A1 (en) 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Rna replicon for versatile and efficient gene expression
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins

Also Published As

Publication number Publication date
WO2021249786A1 (en) 2021-12-16
GB202103142D0 (en) 2021-04-21

Similar Documents

Publication Publication Date Title
EP3321675A4 (en) Blood test kit and blood analysis method
EP3244190A4 (en) Fixture for biological tissue and method for attaching same
EP3321676A4 (en) Blood test kit and blood analysis method
EP3905104A4 (en) Living body detection method and device
GB202006792D0 (en) Method and uses thereof
IL309956A (en) Deoptimized sars-cov-2 variants and methods and uses thereof
EP3564667A4 (en) Blood test kit and blood analysis method
GB201807410D0 (en) Diagnostic method and therapy
EP3401677A4 (en) Living body observation method and living body observation device
GB202101299D0 (en) Diagnostic polypetides and methods
GB202213962D0 (en) Use and method
GB202019767D0 (en) Compostitions and methods
EP3564669A4 (en) Blood analysis method and blood test kit
GB202102391D0 (en) Methods and kits
EP3321679A4 (en) Blood analysis method and blood testing kit
EP3321372A4 (en) Blood analysis method and blood test kit
IL275186A (en) Human anti-grp94 antibodies and uses
EP3703560A4 (en) Living body detection method and apparatus
EP3564666A4 (en) Blood analysis method and blood test kit
EP3564668A4 (en) Blood analysis method and blood test kit
EP3633603A4 (en) Tissue density analysis method and system
GB202005589D0 (en) Medical methods and medical uses
GB202104348D0 (en) Uses and methods
GB2596911B (en) Method and specimen
GB202014725D0 (en) Diagnostic polypeptides and methods

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)